Moody Lynn & Lieberson LLC Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moody Lynn & Lieberson LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 73.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 267 shares of the biopharmaceutical company’s stock after selling 755 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Regeneron Pharmaceuticals were worth $281,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Wealthcare Advisory Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 14.4% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 37 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Regeneron Pharmaceuticals by 11.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock worth $22,283,000 after purchasing an additional 2,412 shares in the last quarter. 180 Wealth Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $218,000. Fifth Third Wealth Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $217,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Regeneron Pharmaceuticals by 22.0% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 2,365 shares of the biopharmaceutical company’s stock valued at $2,276,000 after acquiring an additional 426 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $933.02 on Friday. The firm has a market cap of $102.86 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The business’s fifty day moving average is $1,093.37 and its 200-day moving average is $1,039.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm posted $8.79 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on REGN shares. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Royal Bank of Canada restated an “outperform” rating and issued a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,101.00.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.